CCDC125 inhibitors exert their influence through a variety of biochemical mechanisms, each targeting specific signaling pathways or cellular processes that may involve CCDC125. One class of inhibitors targets kinase activity, which is essential for the phosphorylation and subsequent activation or deactivation of many proteins, including CCDC125. By preventing phosphorylation, these inhibitors can effectively reduce or abolish the functional activity of CCDC125. Another inhibitor class focuses on disrupting specific signaling cascades, such as the PI3K/Akt and MAPK/ERK pathways; these pathways are integral to cellular growth, survival, and differentiation. When these pathways are inhibited, the associated functions of CCDC125, if it is a participant in these cascades, are also likely to be compromised, leading to an overall decrease in its activity.
Further affecting CCDC125 functionality, there are inhibitors that target mTOR, a central regulator of cell growth and proliferation. Inhibition of mTOR could indirectly suppress CCDC125 if it is implicated in mTOR-related signaling. Similarly, other compounds interfere with the cellular stress response, inflammatory pathways, and cell cycle progression by inhibiting JNK, p38 MAPK, and Aurora kinases, respectively. Such inhibition can lead to alterations in CCDC125 activity, provided that CCDC125 operates within these pathways. Moreover, inhibitors disrupting calcium homeostasis and intracellular protein trafficking can also lead to a decline in CCDC125 activity by affecting processes such as calcium-dependent signaling and protein secretion, which may be vital for CCDC125's role in cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can interfere with the phosphorylation state of CCDC125, thereby affecting its function in signaling pathways where phosphorylation is critical. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can disrupt downstream signaling pathways, potentially leading to alterations in CCDC125 activity if it is implicated in PI3K/Akt signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can influence cellular growth and survival pathways, indirectly inhibiting CCDC125 if it interacts with mTOR signaling components. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
A Smoothened (SMO) antagonist that inhibits the Hedgehog signaling pathway, potentially decreasing CCDC125 activity if it is part of the Hedgehog response mechanism. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that disrupts the MAPK/ERK pathway, which could affect CCDC125 activity if it is involved in this signaling cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific inhibitor of MEK that prevents the activation of MAPK/ERK, potentially altering the functional role of CCDC125 within this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can affect the inflammation response and other cellular processes, indirectly modifying CCDC125 function if it is involved in p38 MAPK-regulated pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that could modify cellular responses to stress and apoptosis, potentially altering CCDC125 function if it has a role in JNK-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that disrupts various cellular processes, including those that may involve CCDC125 if it is a component of PI3K-dependent signaling mechanisms. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor that could affect cell cycle progression, potentially influencing CCDC125 if it is associated with mitotic processes. | ||||||